This study will investigate the tolerability and pharmacokinetics of single or multiple doses of Cardeva in patients with stable heart failure. The primary outcomes will be safety parameters. Secondary outcomes will include pharmacokinetic parameters and measures of biological activity.
Latest Information Update: 13 Oct 2006
At a glance
- Drugs B type natriuretic peptide Teva (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacokinetics
- Sponsors CoGenesys
- 13 Oct 2006 Status change
- 31 Jul 2006 New trial record.